MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2
Authors Tang W, Xu P, Wang H, Niu Z, Zhu D, Lin Q, Tang L, Ren L
Received 9 January 2018
Accepted for publication 21 February 2018
Published 24 April 2018 Volume 2018:11 Pages 2319—2332
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Tohru Yamada
Wentao Tang,1,* Pingping Xu,1,* Hong Wang,1,* Zhengchuan Niu,1 Dexiang Zhu,1 Qi Lin,1 Liming Tang,2 Li Ren1
1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; 2Department of General Surgery, Affiliated Changzhou No 2 People’s Hospital, Nanjing Medical University, Changzhou, China
*These authors contributed equally to this work
Background: Growing evidence suggests that miR-150 plays an inhibitory role in various types of cancer. However, the function and underlying mechanisms of miR-150 in triple-negative breast cancer (TNBC) remain unknown.
Patients and methods: miR-150 expression was detected by qRT-PCR and ISH in TNBC tumor and adjacent normal breast tissues. miR-150 function was analyzed by wound healing and transwell assay in vitro and mouse lung metastasis model in vivo. mRNA microarray, qRT-PCR, western blotting and luciferase assay were used to identify the target gene of miR-150. HMGA2 over-expression plasmid was co-transfected with miR-150 to study the role of miR-150 through regulating HMGA2.
Results: We found that miR-150 was down-regulated in TNBC tumor tissues compared to corresponding adjacent, normal breast tissues, and was correlated with decreased lymph-node metastasis. Ectopic expression of miR-150 suppressed TNBC cell migration in vitro and metastasis in vivo. Mechanistic study revealed that miR-150 down-regulates HMGA2 by directly targeting its mRNA. Moreover, the suppression of cell migration caused by miR-150 is relieved by over-expression of HMGA2, suggesting that miR-150 inhibits migration of TNBC cells by down-regulating HMGA2.
Conclusion: This work indicates that the miR-150/HMGA2 axis may serve as a treatment marker in TNBC.
Keywords: miR-150, HMGA2, triple-negative breast cancer, metastasis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]